These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 29316191)

  • 21. Immunoglobulin A and liver diseases.
    Inamine T; Schnabl B
    J Gastroenterol; 2018 Jun; 53(6):691-700. PubMed ID: 29075899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future.
    Lang S; Schnabl B
    Cell Host Microbe; 2020 Aug; 28(2):233-244. PubMed ID: 32791115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Dysbiosis for the Treatment of Liver Disease.
    Anand G; Zarrinpar A; Loomba R
    Semin Liver Dis; 2016 Feb; 36(1):37-47. PubMed ID: 26870931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.
    Chopyk DM; Grakoui A
    Gastroenterology; 2020 Sep; 159(3):849-863. PubMed ID: 32569766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
    Ferrere G; Wrzosek L; Cailleux F; Turpin W; Puchois V; Spatz M; Ciocan D; Rainteau D; Humbert L; Hugot C; Gaudin F; Noordine ML; Robert V; Berrebi D; Thomas M; Naveau S; Perlemuter G; Cassard AM
    J Hepatol; 2017 Apr; 66(4):806-815. PubMed ID: 27890791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gut microbiota in autoimmunity: potential for clinical applications.
    Kim D; Yoo SA; Kim WU
    Arch Pharm Res; 2016 Nov; 39(11):1565-1576. PubMed ID: 27444041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intestinal microbiota and nonalcoholic steatohepatitis.
    Brandl K; Schnabl B
    Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature.
    Giuffrè M; Campigotto M; Campisciano G; Comar M; Crocè LS
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G889-G906. PubMed ID: 32146836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut microbiota and liver diseases.
    Minemura M; Shimizu Y
    World J Gastroenterol; 2015 Feb; 21(6):1691-702. PubMed ID: 25684933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation.
    Hendrikx T; Schnabl B
    J Intern Med; 2019 Jul; 286(1):32-40. PubMed ID: 30873652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver transplantation: Rejection and tolerance.
    Taner T
    Liver Transpl; 2017 Oct; 23(S1):S85-S88. PubMed ID: 28779559
    [No Abstract]   [Full Text] [Related]  

  • 35. The role of gut microbiota in intestinal and liver diseases.
    Hrncir T; Hrncirova L; Kverka M; Tlaskalova-Hogenova H
    Lab Anim; 2019 Jun; 53(3):271-280. PubMed ID: 30580671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver-Microbiome Axis in Health and Disease.
    Adolph TE; Grander C; Moschen AR; Tilg H
    Trends Immunol; 2018 Sep; 39(9):712-723. PubMed ID: 29843959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of the gut microbiota in the pathology and prevention of liver disease.
    Altamirano-Barrera A; Uribe M; Chávez-Tapia NC; Nuño-Lámbarri N
    J Nutr Biochem; 2018 Oct; 60():1-8. PubMed ID: 29653359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alcohol or Gut Microbiota: Who Is the Guilty?
    Meroni M; Longo M; Dongiovanni P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial proteins: intestinal guards to protect against liver disease.
    Hendrikx T; Schnabl B
    J Gastroenterol; 2019 Mar; 54(3):209-217. PubMed ID: 30392013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.
    Ma J; Zhou Q; Li H
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 29035308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.